BioWorld

July 8, 2008

Putative Cancer Promoter Might be Tumor Suppressor

DOE Spinout Aims to Harness Nell1 for Cardio Therapies

Agios Will Use $33M Series A to Target Cancer Metabolism

Agios Pharmaceuticals said it plans to use the proceeds from a just-completed $33 million Series A financing to establish a product and biology platform focused on a new class of drugs that regulate cancer metabolism. (BioWorld Today) Read More

Michigan Fund Uses $50M Pot to Woo Biotechs to Kalamazoo

Today's news in brief

BioWorld

BioWorld briefs for April 16, 2026.

MMP inhibitors divulged in Accure Therapeutics patent

BioWorld Science

Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 14, 2026

Selective CBL-B inhibitor with improved safety profile disclosed

BioWorld Science

CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...

MSD discloses new HCN1/2 blockers

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...

BioWorld

July 8, 2008

Putative Cancer Promoter Might be Tumor Suppressor

DOE Spinout Aims to Harness Nell1 for Cardio Therapies

Other News To Note

Clinic Roundup

Agios Will Use $33M Series A to Target Cancer Metabolism

Michigan Fund Uses $50M Pot to Woo Biotechs to Kalamazoo

Today's news in brief

MMP inhibitors divulged in Accure Therapeutics patent

News in brief

Selective CBL-B inhibitor with improved safety profile disclosed

MSD discloses new HCN1/2 blockers